This review aims to explore the diverse strategies for AAT gene therapy targeting the pulmonary manifestations of AAT deficiency, as well as the current advancements in translating AAT gene therapy into clinical practice. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.